tiprankstipranks
BeOne Medicines Ltd (HK:6160)
:6160
Hong Kong Market
6160
BeOne Medicines Ltd
RESEARCH TOOLSreports
Want to see HK:6160 full AI Analyst Report?

BeOne Medicines Ltd (6160) Stock Forecast & Price Target

25 Followers
See the Price Targets and Ratings of:

6160 Analyst Ratings

Strong Buy
15Ratings
Strong Buy
15 Buy
0 Hold
0 Sell
Based on 15 analysts giving stock ratings to
BeOne
Medicines Ltd
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6160 Stock 12 Month Forecast

Average Price Target

HK$258.90
▲(34.00% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for BeOne Medicines Ltd in the last 3 months. The average price target is HK$258.90 with a high forecast of HK$297.44 and a low forecast of HK$225.60. The average price target represents a 34.00% change from the last price of HK$193.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"146":"HK$146","184":"HK$184","222":"HK$222","260":"HK$260","298":"HK$298"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":297.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$297.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":258.89666666666665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$258.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":225.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$225.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[146,184,222,260,298],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170.4,180.1723076923077,189.9446153846154,199.71692307692308,209.48923076923077,219.26153846153846,229.03384615384616,238.80615384615385,248.57846153846154,258.35076923076923,268.12307692307695,277.8953846153846,287.6676923076923,{"y":297.44,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170.4,177.20743589743591,184.0148717948718,190.8223076923077,197.62974358974358,204.4371794871795,211.24461538461537,218.05205128205128,224.85948717948716,231.66692307692307,238.47435897435895,245.28179487179486,252.08923076923077,{"y":258.89666666666665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170.4,174.64615384615385,178.8923076923077,183.13846153846154,187.3846153846154,191.63076923076923,195.87692307692308,200.12307692307692,204.36923076923077,208.6153846153846,212.86153846153846,217.1076923076923,221.35384615384615,{"y":225.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":147.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$297.44Average Price TargetHK$258.90Lowest Price TargetHK$225.60
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Macquarie Analyst forecast on HK:6160
Unknown Analyst
Macquarie
Not Ranked
Macquarie
HK$257
Buy
33.02%
Upside
Reiterated
07/13/26
BeOne Medicines Ltd (6160) Receives a Buy from Macquarie
HSBC Analyst forecast on HK:6160
Unknown Analyst
HSBC
Not Ranked
HSBC
HK$225.6
Buy
16.77%
Upside
Reiterated
07/10/26
HSBC Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
Huafu Securities Analyst forecast on HK:6160
Unknown Analyst
Huafu Securities
Not Ranked
Huafu Securities
HK$297.44
Buy
53.95%
Upside
Reiterated
07/06/26
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
UBS Analyst forecast on HK:6160
Unknown Analyst
UBS
Not Ranked
UBS
HK$279→HK$273.6
Buy
41.61%
Upside
Reiterated
07/01/26
UBS Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
CICC Analyst forecast on HK:6160
Unknown Analyst
CICC
Not Ranked
CICC
HK$250
Buy
29.40%
Upside
Reiterated
06/03/26
BeOne Medicines Ltd (6160) Gets a Buy from CICC
Citi Analyst forecast on HK:6160
Unknown Analyst
Citi
Not Ranked
Citi
HK$271.8
Buy
40.68%
Upside
Reiterated
06/02/26
Citi Keeps Their Buy Rating on BeOne Medicines Ltd (6160)
Bank of America Securities Analyst forecast on HK:6160
David Li
Bank of America Securities
Bank of America Securities
HK$243.8
Buy
26.19%
Upside
Reiterated
05/21/26
BeOne Medicines Ltd (6160) Gets a Buy from Bank of America Securities
Citic Securities Analyst forecast on HK:6160
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$240→HK$234
Buy
21.12%
Upside
Reiterated
05/12/26
Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
CMBC International Analyst forecast on HK:6160
Unknown Analyst
CMBC International
Not Ranked
CMBC International
HK$278.85
Buy
44.33%
Upside
Reiterated
05/10/26
BeOne Medicines Ltd (6160) Gets a Buy from CMBC International
Bank of China Analyst forecast on HK:6160
Unknown Analyst
Bank of China
Not Ranked
Bank of China
HK$240
Buy
24.22%
Upside
Reiterated
05/07/26
Bank of China Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)
CLSA Analyst forecast on HK:6160
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$291.9
Buy
51.09%
Upside
Reiterated
05/07/26
BeOne Medicines Ltd (6160) Gets a Buy from CLSA
CMB International Securities Analyst forecast on HK:6160
Unknown Analyst
CMB International Securities
Not Ranked
CMB International Securities
HK$235.46
Buy
21.87%
Upside
Reiterated
05/07/26
CMB International Securities Remains a Buy on BeOne Medicines Ltd (6160)
UOB Kay Hian Analyst forecast on HK:6160
Unknown Analyst
UOB Kay Hian
Not Ranked
UOB Kay Hian
HK$257
Buy
33.02%
Upside
Reiterated
05/07/26
UOB Kay Hian Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)
DBS Analyst forecast on HK:6160
Mark Kong CFA
DBS
DBS
HK$290
Buy
50.10%
Upside
Reiterated
05/07/26
BeOne Medicines Ltd (6160) Receives a Buy from DBS
Morgan Stanley Analyst forecast on HK:6160
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$237
Buy
22.67%
Upside
Reiterated
05/06/26
Morgan Stanley Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Macquarie Analyst forecast on HK:6160
Unknown Analyst
Macquarie
Not Ranked
Macquarie
HK$257
Buy
33.02%
Upside
Reiterated
07/13/26
BeOne Medicines Ltd (6160) Receives a Buy from Macquarie
HSBC Analyst forecast on HK:6160
Unknown Analyst
HSBC
Not Ranked
HSBC
HK$225.6
Buy
16.77%
Upside
Reiterated
07/10/26
HSBC Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
Huafu Securities Analyst forecast on HK:6160
Unknown Analyst
Huafu Securities
Not Ranked
Huafu Securities
HK$297.44
Buy
53.95%
Upside
Reiterated
07/06/26
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
UBS Analyst forecast on HK:6160
Unknown Analyst
UBS
Not Ranked
UBS
HK$279→HK$273.6
Buy
41.61%
Upside
Reiterated
07/01/26
UBS Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
CICC Analyst forecast on HK:6160
Unknown Analyst
CICC
Not Ranked
CICC
HK$250
Buy
29.40%
Upside
Reiterated
06/03/26
BeOne Medicines Ltd (6160) Gets a Buy from CICC
Citi Analyst forecast on HK:6160
Unknown Analyst
Citi
Not Ranked
Citi
HK$271.8
Buy
40.68%
Upside
Reiterated
06/02/26
Citi Keeps Their Buy Rating on BeOne Medicines Ltd (6160)
Bank of America Securities Analyst forecast on HK:6160
David Li
Bank of America Securities
Bank of America Securities
HK$243.8
Buy
26.19%
Upside
Reiterated
05/21/26
BeOne Medicines Ltd (6160) Gets a Buy from Bank of America Securities
Citic Securities Analyst forecast on HK:6160
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$240→HK$234
Buy
21.12%
Upside
Reiterated
05/12/26
Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
CMBC International Analyst forecast on HK:6160
Unknown Analyst
CMBC International
Not Ranked
CMBC International
HK$278.85
Buy
44.33%
Upside
Reiterated
05/10/26
BeOne Medicines Ltd (6160) Gets a Buy from CMBC International
Bank of China Analyst forecast on HK:6160
Unknown Analyst
Bank of China
Not Ranked
Bank of China
HK$240
Buy
24.22%
Upside
Reiterated
05/07/26
Bank of China Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)
CLSA Analyst forecast on HK:6160
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$291.9
Buy
51.09%
Upside
Reiterated
05/07/26
BeOne Medicines Ltd (6160) Gets a Buy from CLSA
CMB International Securities Analyst forecast on HK:6160
Unknown Analyst
CMB International Securities
Not Ranked
CMB International Securities
HK$235.46
Buy
21.87%
Upside
Reiterated
05/07/26
CMB International Securities Remains a Buy on BeOne Medicines Ltd (6160)
UOB Kay Hian Analyst forecast on HK:6160
Unknown Analyst
UOB Kay Hian
Not Ranked
UOB Kay Hian
HK$257
Buy
33.02%
Upside
Reiterated
05/07/26
UOB Kay Hian Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)
DBS Analyst forecast on HK:6160
Mark Kong CFA
DBS
DBS
HK$290
Buy
50.10%
Upside
Reiterated
05/07/26
BeOne Medicines Ltd (6160) Receives a Buy from DBS
Morgan Stanley Analyst forecast on HK:6160
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$237
Buy
22.67%
Upside
Reiterated
05/06/26
Morgan Stanley Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
KURAKura Oncology
CSTLCastle Biosciences
VKTXViking Therapeutics
ATECAlphatec Holdings
TRVITrevi Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeOne Medicines Ltd

3 Months
Matthew YanCLSA
Success Rate
6/10 ratings generated profit
60%
Average Return
+1.26%
Copying Matthew Yan's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +1.26% per trade.
1 Year
Matthew YanCLSA
Success Rate
7/10 ratings generated profit
70%
Average Return
+29.76%
Copying Matthew Yan's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +29.76% per trade.
2 Years
Matthew YanCLSA
Success Rate
9/10 ratings generated profit
90%
Average Return
+46.03%
Copying Matthew Yan's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +46.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6160 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
1
1
4
7
9
Buy
5
5
12
9
11
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
6
16
16
20
In the current month, 6160 has received 20 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6160 average Analyst price target in the past 3 months is 258.90.
Each month's total comprises the sum of three months' worth of ratings.

6160 Financial Forecast

6160 Earnings Forecast

Next quarter’s earnings estimate for 6160 is HK$0.95 with a range of HK$0.37 to HK$2.13. The previous quarter’s EPS was HK$1.18. 6160 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 6160 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6160 is HK$0.95 with a range of HK$0.37 to HK$2.13. The previous quarter’s EPS was HK$1.18. 6160 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 6160 has Performed in-line its overall industry.

6160 Sales Forecast

Next quarter’s sales forecast for 6160 is HK$12.62B with a range of HK$12.07B to HK$13.58B. The previous quarter’s sales results were HK$11.83B. 6160 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 6160 has Performed in-line its overall industry.
Next quarter’s sales forecast for 6160 is HK$12.62B with a range of HK$12.07B to HK$13.58B. The previous quarter’s sales results were HK$11.83B. 6160 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 6160 has Performed in-line its overall industry.

6160 Stock Forecast FAQ

What is HK:6160’s average 12-month price target, according to analysts?
Based on analyst ratings, BeOne Medicines Ltd’s 12-month average price target is 258.90.
    What is HK:6160’s upside potential, based on the analysts’ average price target?
    BeOne Medicines Ltd has 34.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BeOne Medicines Ltd a Buy, Sell or Hold?
          BeOne Medicines Ltd has a consensus rating of Strong Buy, which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
            What is BeOne Medicines Ltd’s share price target?
            The average share price target for BeOne Medicines Ltd is 258.90. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$297.44 ,and the lowest forecast is HK$225.60. The average share price target represents 34.00% Increase from the current price of HK$193.2.
              What do analysts say about BeOne Medicines Ltd?
              BeOne Medicines Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of BeOne Medicines Ltd?
                To buy shares of HK:6160, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.